On February 22, 2021, Bristol Myers Squibb’s wholly-owned subsidiary Celgene Corporation (‘Celgene’) also issued a notice of redemption to The Bank of New York Mellon Trust Company, N.A., as trustee, (together, with The Bank of New York Mellon, the ‘Trustees’), to redeem (i) all of Celgene’s 4.000% Notes due 2023 (CUSIP No. 151020AJ3), originally issued on August 6, 2013, that remain outstanding after the early settlement of the previously announced tender offers (the ‘Celgene 4.000% Notes’) and (ii) all of Celgene’s 3.250% Notes due 2023 (CUSIP No. 151020BA1), originally issued on February 20, 2018 (the ‘Celgene 3.250% Notes’ and, together with the Celgene 4.000% Notes, the ‘Celgene Notes’; the BMS Notes with the Celgene Notes, the ‘Notes’) at the applicable ‘make whole’ redemption prices (the ‘Celgene Redemption Prices’ and, together with the BMS Redemption Prices, the ‘Redemption Prices’) to be calculated as set forth in the indentures pursuant to which the Celgene Notes were issued, plus accrued and unpaid interest to, but excluding, the 4.000% Redemption Date with respect to the Celgene 4.000% Notes and the 3.250% Redemption Date with respect to the Celgene 3.250 % Notes. Payment of the applicable Redemption Prices will be made on or after the applicable Redemption Dates only upon presentation and surrender of the Notes to the Trustees, and the Trustees will determine which portions of the Notes will be redeemed. On the applicable Redemption Date, the applicable Redemption Prices will become due and payable on the relevant Notes and, unless Bristol Myers Squibb or Celgene, as the case may be, defaults in the payment of such Redemption Prices, interest on such Notes will cease to accrue on and after the applicable Redemption Date. Bristol Myers Squibb and Celgene will use cash on hand to finance the redemption of the Notes at the Redemption Prices. Following the early settlement of the previously announced tender offers and the settlement of the ‘make whole’ redemptions described above, Bristol Myers Squibb will have purchased approximately $4.0 billion in aggregate purchase price for its debt securities as previously disclosed.